Geneva, Switzerland, May 4th 2015 – EspeRare today announced that the European Medicines Agency (EMA) has granted an Orphan Drug Designation (ODD) for rimeporide, its lead compound for the treatment of Duchenne muscular dystrophy (DMD). DMD is a rare, life-threatening disease affecting boys early in childhood that causes muscle weakness and muscle loss. It is the most common and serious form of paediatric muscular dystrophies.
Find an actor

CMEF 201811.04.2018

China Medical Equipment Fair 2018 Shanghai - China April 11-14, 2018

Le Challenge Debiopharm Inartis

La qualité de vie du patient en cours de traitement "Qui pourra changer le monde dans lequel nous vivons?”
Print this page Download this page (PDF) Recommend this page to a friend

Contact us

BioAlps Association
Ch. du Pré-Fleuri 3
CH - 1228 Plan-les Ouates
+41 22 304 40 40
+41 22 304 40 70

Subscribe to our newsletter

Find us on LinkedIn